1748-5827/asset/JSAP_left.gif?v=1&s=1230053d6e2962fa35f93ffb0ee07e5141755e6d)
1748-5827/asset/JSAP_right.gif?v=1&s=4a52cc4d45cba4212e11fad24d9b072b7cf8348a)
Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs
Article first published online: 6 DEC 2006
DOI: 10.1111/j.1748-5827.2006.00231.x
Additional Information
How to Cite
Passmore, C. A., Sherington, J. and Stegemann, M. R. (2007), Efficacy and safety of cefovecin (Convenia™) for the treatment of urinary tract infections in dogs. Journal of Small Animal Practice, 48: 139–144. doi: 10.1111/j.1748-5827.2006.00231.x
Publication History
- Issue published online: 6 DEC 2006
- Article first published online: 6 DEC 2006
- Abstract
- Article
- References
- Cited By
Objectives: To determine the efficacy and safety of cefovecin (ConveniaTM; Pfizer Animal Health) in the treatment of urinary tract infections in dogs.
Methods: A multi-centre, blinded, randomised study was conducted in 129 dogs with urinary tract infections. Cephalexin (RilexineTM) administered twice daily at 15 mg/kg bodyweight orally for 14 days was compared with a single, subcutaneous injection of cefovecin (ConveniaTM) in dogs. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.
Results: One hundred and twenty-nine dogs were included in efficacy assessments. Escherichia coli was eliminated in 90·5 per cent of cefovecin-treated dogs compared with 52·9 per cent of cephalexin-treated dogs (P=0·0004). Overall cure rates for dogs with Escherichia coli infections were 79·1 per cent for cefovecin and 36·4 per cent for cephalexin-treated dogs (P=0·0003). There were no suspected adverse drug reactions attributed to treatment with cefovecin or cephalexin.
Clinical Significance: Cefovecin was shown to be an effective and safe treatment for urinary tract infections.